U.S. Healthtech Stock News

Proto Labs (PRLB) has quietly put together a strong run this year, with the stock up about 37% year to date and roughly 20% over the past year, outpacing many industrial peers. See our latest analysis for Proto Labs. That momentum has not come out of nowhere, with a 7.5% 1 month share price return and a 20.2% 1 year total shareholder return suggesting investors are steadily warming to Proto Labs growth and risk profile. If Proto Labs has you rethinking your watchlist, this is a good moment to...

Samsara Inc. recently reported its third-quarter 2026 results, with revenue rising to US$415.98 million and net income reaching US$7.77 million, marking its first quarter of GAAP profitability after a loss in the prior year period. The company paired this milestone with a 29% year-on-year increase in Annual Recurring Revenue, record additions of large enterprise customers, and growing international traction, underscored by customer case studies such as Swissport’s incident and vehicle damage...

Earlier this month, Equifax launched Income Qualify, a tool that uses verified income and employment data from The Work Number to help mortgage lenders assess borrowers earlier in the prequalification and pre-approval process. By pairing Equifax credit files with upfront income verification and offering lower-priced VantageScore mortgage scores, the company is pushing deeper into lenders’ workflow and cost decisions. We’ll now examine how earlier access to verified income data for mortgage...

Brookfield Infrastructure Partners (NYSE:BIP) just renewed its normal course issuer bids, giving management fresh approval to buy back and cancel a meaningful slice of LP units, preferred units, and exchangeable shares over the next year. See our latest analysis for Brookfield Infrastructure Partners. The timing of these renewed buybacks lines up with a clear turn in sentiment. The latest share price of $35.10 and a solid 90 day share price return of 14.48% support a 10.76% one year total...

Wondering if iQIYI at around $2 a share is a hidden bargain or a value trap? You are not alone, and this is exactly what we are going to unpack. The stock is roughly flat over the last week, down 8.1% over the past month and about 11% over the last year, after a brutal 88.2% slide over five years that still shapes how the market views its risk and recovery potential. Recent headlines have centered on iQIYI's ongoing push into premium originals and partnerships in China as it tries to...

If you are wondering whether Turning Point Brands is still a smart buy after its big run up, you are not alone. This article is going to unpack exactly what the current price might be baking in. The stock has climbed 6.0% over the last week, 4.1% over the last month, and is now up an eye catching 72.5% year to date, with a massive 430.9% gain over three years and 151.2% over five years that has clearly changed how the market views its prospects. Recent attention around Turning Point Brands...

Crinetics Pharmaceuticals (CRNX) just hit an important milestone, as it has dosed the first patient in its Phase 1/2 BRAVESST2 trial of CRN09682 for SST2 positive neuroendocrine tumors and other SST2 expressing solid tumors. See our latest analysis for Crinetics Pharmaceuticals. The BRAVESST2 milestone comes after a powerful run in the share price, with a roughly 45% 3 month share price return helping claw back some of the softer year to date move and setting up stronger long term momentum...

Preformed Line Products (PLPC) just gave income focused investors something new to consider, approving a 5% hike to its quarterly dividend, the first increase since the company listed in 2001. See our latest analysis for Preformed Line Products. The move lands after a strong run, with the latest share price at $231.5 and an impressive year to date share price return of about 80%. The five year total shareholder return of roughly 267% shows that long term momentum has been firmly building. If...

NextNav Inc. recently began operating its 5G Positioning, Navigation and Timing (PNT) Network in Santa Clara County, California, using multiple fixed base stations, a standalone 5G core, and its 3D PNT architecture to provide a terrestrial complement and backup to GPS. This deployment uniquely tests a standards-compliant 5G Positioning Reference Signal under real-world conditions, an important step toward offering resilient 3D location and timing services for critical infrastructure, public...

Newell Brands (NWL) just paired a sweeping productivity overhaul, including more than 900 job cuts and 20 Yankee Candle store closures, with lowered Q4 guidance as Latin America sales improve more slowly than management expected. See our latest analysis for Newell Brands. Despite the sweeping restructuring moves, the share price has shown a 1 month share price return of about 18% and a 7 day share price return near 5%. However, that bounce sits against a much steeper year to date share price...

Navan (NAVN) has been under pressure lately, with the stock sliding about 19% over the past month and roughly 30% year to date. This has raised fresh questions about how investors should value its AI-driven travel platform. See our latest analysis for Navan. Zooming out, that sharp recent slide in Navan’s share price sits on top of an already weak year to date share price return. This suggests momentum has clearly cooled as investors reassess both growth runway and execution risk. If Navan’s...

BioMarin Pharmaceutical (BMRN) has quietly slid about 20% this year, even as revenue and net income keep growing. That disconnect is exactly what has value focused biotech investors taking a closer look. See our latest analysis for BioMarin Pharmaceutical. At around $52.99 per share, BioMarin’s roughly 20% year to date share price decline and steep three and five year total shareholder return drawdown suggest sentiment has cooled. At the same time, steady revenue and profit growth hint that...

Despite an already strong run, Arteris, Inc. ( NASDAQ:AIP ) shares have been powering on, with a gain of 27% in the...

Gold Royalty (NYSEAM:GROY) just closed a $90 million follow on equity offering at around $4 a share, a sizable capital raise that immediately reshapes the balance sheet and future deal making capacity. See our latest analysis for Gold Royalty. That capital raise caps a hectic stretch that also included underwriter changes and a special call about acquiring a cash flowing gold and copper royalty in Brazil. The stock’s 230.65% year to date share price return alongside a 222.83% one year total...

Wondering if Western Union at around $9.61 is a bargain or a value trap? This article will walk you through what the numbers are really saying about the stock. Despite a tough longer term run, with the share price still down 40.8% over 5 years, the stock has bounced recently, gaining 7.6% over the last week and 7.9% over the past month, even though it remains 8.0% lower year to date and 2.5% down over the last year. Part of this shift in sentiment reflects ongoing strategic moves to...

Danaher (DHR) just picked up a fresh Buy rating from Goldman Sachs, and the timing lines up with improving sentiment in life sciences tools, especially bioprocessing equipment where demand signals are finally turning. See our latest analysis for Danaher. The stock has quietly put together a solid run, with a 90 day share price return of 22.27 percent and a 30 day gain of 7.68 percent. The 5 year total shareholder return of 19.30 percent shows long term compounding even though the 1 year total...

Red Rock Resorts (RRR) has quietly put together a strong run this year, and the stock’s recent move higher is prompting investors to revisit how its Las Vegas focused casino portfolio supports that momentum. See our latest analysis for Red Rock Resorts. That 6.4% one day share price jump to about $61 signals investors are leaning back into Red Rock’s local Las Vegas growth story, with year to date share price returns already strong and longer term total shareholder returns reinforcing that...

If you have been wondering whether MP Materials is still a smart way to play the rare earths theme after its huge run, this breakdown will help you decide if the current price still offers value or if most of the upside is already priced in. The stock has surged an eye catching 266.1% year to date and 206.2% over the last 12 months, even after a modest pullback of around 3% over the past week and month, which naturally raises questions about how much future upside is left versus downside...

Cigna Group (CI) is drawing fresh attention after rolling out a rebate free pharmacy benefit model that aims to simplify drug pricing, cut upfront costs, and potentially reshape how pharmacy benefit managers operate. See our latest analysis for Cigna Group. Investors seem to be slowly warming to the story, with a 1 day share price return of 3.68 percent helping to offset a 90 day share price return of minus 10.07 percent, while the 5 year total shareholder return of 46.87 percent still points...

Griffon (GFF) has quietly outperformed the broader market over the past week and month, and that steady climb is starting to draw attention from investors looking for durable industrial exposure. See our latest analysis for Griffon. The recent 1 month share price return of 7.88 percent, on top of a robust 3 year total shareholder return of 144.18 percent, suggests momentum is still firmly on Griffon’s side as investors reassess its growth and cash generation story. If Griffon’s run has you...

Wondering if Alnylam Pharmaceuticals at around $412 a share is still a smart buy after its huge run, or if the upside has already been priced in. The stock is down 11.3% over the last week and 8.7% over the past month, but even after that pullback it is still up 76.6% year to date and 68.2% over the last 12 months. Those moves have come as investors refocus on Alnylam's RNAi drug pipeline, major partnerships with big pharma, and the growing commercial traction of its approved therapies. The...

Wondering if Perimeter Solutions is still a smart buy after its big run up, or if the easy money has already been made? This article will unpack whether the current price really matches the underlying value. The stock has climbed 2.6% over the last week and 11.9% over the past month, but the real eye catcher is its 126.8% gain year to date and 123.3% return over the last year, on top of a 229.7% rise over three years. That surge has come as investors refocus on wildfire prevention and...

CS Disco, Inc. ( NYSE:LAW ) shares have continued their recent momentum with a 26% gain in the last month alone...

Abbott Laboratories (ABT) just widened the audience for its Lingo glucose sensor by rolling it out on Android, pairing that step with fresh real world data on how protein intake shapes daily glucose control. See our latest analysis for Abbott Laboratories. Those Lingo updates and new Ensure protein launches land while Abbott’s 1 year total shareholder return of about 10 percent edges ahead of its year to date share price return near 9 percent, suggesting steady long term momentum despite...